Pharmaceuticals

Anti-Cancer MAbS Market Expansion Outlook: $102.74 Billion by 2029 Forecast

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Anti-Cancer MAbS Market From 2025 To 2034?

The anti-cancer MAbS market size has experienced strong growth in recent years. It is projected to increase from $65.35 billion in 2024 to $71.25 billion in 2025, with a compound annual growth rate (CAGR) of 9.0%. This historical expansion can be attributed to various factors, including rising cancer incidence rates, an expanding understanding of cancer biology, the emergence of personalized medicine approaches, heightened investment in research and development, and increasing patient awareness and demand.

The anti-cancer MAbS market is projected to experience substantial expansion over the coming years. This market is forecast to reach $102.74 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.6%. This anticipated growth is driven by progress in immunotherapy, the rising uptake of combination treatments, the development of next-generation mAbs, worldwide initiatives to combat the cancer burden, and the broadening of patient access programs. Key trends identified for this period encompass breakthroughs in drug delivery methods, the incorporation of artificial intelligence into drug discovery processes, strategic alliances and partnerships within the pharmaceutical sector, ongoing developments in biotechnology, and advancements in CAR-T cell therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9041&type=smp

What Are The Drivers Pushing New Developments In The Anti-Cancer MAbS Market?

The expanding global prevalence of cancer is anticipated to propel the growth of the anticancer MABs market. Cancer, a chronic and long-lasting disease, sees its impact addressed by anticancer monoclonal antibodies (mAbs). These mAbs are specifically engineered versions of the immune system’s own antibodies, designed to bind to particular proteins on cancerous cells and subsequently target and destroy them. As a direct consequence, the increasing incidence of cancer naturally elevates the demand for the anticancer MABs market. A notable example is the projection from January 2022 by PubMed, a US-based biomedical and life sciences journal, estimating around 1.9 million new cancer cases globally and 609,360 cancer deaths in the United States. Therefore, the rising prevalence of cancer worldwide is a primary driver for the expansion of the anticancer mAbs market.

What Are The Major Segments Identified In The Anti-Cancer MAbS Market?

The anti-cancer mabs market covered in this report is segmented –

1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types

2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications

3) By End User: Hospitals, Research Institutes, Other End Users

Subsegments:

1) By Murine Antibodies: Murine IgG, Murine IgM, Other Murine Isotypes

2) By Chimeric Antibodies: Chimeric IgG, Chimeric IgM, Other Chimeric Isotypes

3) By Humanized Antibodies: Humanized IgG, Humanized IgM, Other Humanized Isotypes

4) By Other Types: Fully Human Antibodies, Bispecific Antibodies, Conjugated Antibodies, Other Novel Formats

How Are Emerging Market Trends Shaping The Anti-Cancer MAbS Industry Landscape?

Product innovations represent a significant and increasingly popular trend within the anticancer mAbs market. Major companies active in this sector are introducing more effective and precisely targeted cancer treatments, such as mAb drugs, to enhance their market position. For instance, in May 2022, the Switzerland-based pharmaceutical company Roche Holding AG introduced PHESGO. This product, PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf), offers a distinctive monoclonal antibody (mAb) combination therapy for HER2-positive early breast cancer. Administered as a subcutaneous (under the skin) injection, it integrates the two mAbs, pertuzumab and trastuzumab, with the enzyme hyaluronidase. The incorporation of hyaluronidase, an enzyme known to boost the absorption of mAbs, facilitates the subcutaneous delivery of the treatment rather than through intravenous means.

Which Global Market Leaders Are Shaping The Future Of The Anti-Cancer MAbS Sector?

Major companies operating in the anti-cancer mabs market include Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, Kite Pharma, ADC Therapeutics, MacroGenics Inc., BioXcel Therapeutics, Zymeworks Inc., Exelixis Inc., Blueprint Medicines, Erytech Pharma, Oncopeptides AB

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

Which Regional Markets Are Contributing Most To The Anti-Cancer MAbS Industry Expansion?

North America was the largest region in the anti-cancer MAbS market in 2024. Asia-Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Anti-Cancer MAbS Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9041&type=smp

Browse Through More Reports Similar to the Global Anti-Cancer MAbS Market 2025, By The Business Research Company

Pain Management Devices And Therapies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report

Metabolomics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Isothermal Nucleic Acid Amplification Technology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795